Preferred Label : Hyperphenylalaninemia, bh4-deficient, a;
Symbol : HPABH4A;
CISMeF acronym : HPABH4A;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Hyperphenylalaninemia, tetrahydrobiopterin-deficient, due to pts deficiency; 6-pyruvoyl-tetrahydropterin synthase deficiency; Pts deficiency; PTSD; PTPSD;
Included titles and symbols : Hyperphenylalaninemia, bh4-deficient, due to partial pts deficiency;
Description : Tetrahydrobiopterin (BH4)-deficient hyperphenylalaninemia (HPA) comprises a genetically
heterogeneous group of progressive neurologic disorders caused by autosomal recessive
mutations in the genes encoding enzymes involved in the synthesis or regeneration
of BH4. BH4 is a cofactor for phenylalanine hydroxylase (PAH; 612349), tyrosine hydroxylase
(TH; 191290) and tryptophan hydroxylase (TPH1; 191060), the latter 2 of which are
involved in neurotransmitter synthesis. The BH4-deficient HPAs are characterized phenotypically
by hyperphenylalaninemia, depletion of the neurotransmitters dopamine and serotonin,
and progressive cognitive and motor deficits (Dudesek et al., 2001).;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the 6-@pyruvoyl-tetrahydropterin synthase gene PTS, (612719.0001);
Laboratory abnormalities : Hyperphenylalaninemia; Decreased homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) in CSF; Increased neopterin in urine and CSF; Decreased or absent PTS activity;
Prefixed ID : #261640;
Origin ID : 261640;
UMLS CUI : C0878676;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT